Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Lazard enters its October 22 earnings report down 19% over the past month, trading at $36.36, while the advisory sector around it has largely held firmer ground. That gap between Lazard and peers is the central tension this week.
Short interest in Lazard is genuinely elevated, and it has been sticky. Bears hold nearly 10% of the free float, a level that has barely budged over the past six weeks despite some daily noise. The official FINRA fortnightly figure put short shares at 9.93 million as of mid-September, with 8.65 days to cover. That said, the borrow market shows no signs of stress: availability is extremely loose at 1,412%, meaning there are roughly 14 shares available to borrow for every one already lent out. Cost to borrow is barely half a percent. Shorts are not squeezed, and getting into a new position remains cheap. Options confirm the cautious lean. The put/call ratio has risen to 1.13, above its 20-day average of 0.94, though the z-score of 0.77 is not yet extreme. What is notable in the PCR history is the sharp structural shift: before September 21 the ratio ran consistently below 0.70, then it reset sharply higher and has stayed there. That kink in the series marks a meaningful change in how options traders are positioned relative to the last earnings cycle.
The Street has been cutting targets in one direction only. Goldman Sachs, which carries a Sell rating, lowered its target this week from $42 to $36, a level that now sits essentially at the current price. UBS lowered to $40 on the same day, maintaining Neutral. Both moves came within the last seven days and narrow the implied upside from the mean consensus target of $44.88 to around 23%. Morgan Stanley cut its Underweight target in July, and Keefe, Bruyette and Woods has trimmed twice since then. Argus Research is the lone bull among recent movers, but its Buy-rated target of $52 was set in May and has not been revisited. The factor score picture adds texture: the dividend score ranks in the 95th percentile of the universe, reflecting what has historically been a generous yield policy, though the dividend data in this snapshot is stale and should not be taken as current. The short score rank of 18 out of 100 confirms that short positioning here is in the more-elevated part of the distribution. EPS momentum over 90 days is weak at the 14th percentile, though the 30-day reading has recovered sharply to the 90th, a split worth watching as the October print approaches.
Peer performance this week adds another layer of friction. EVR gained 3.7% on the week while Lazard added only 1.6%. PJT fell 3.6% and GS lost 2.1%, so the sector is mixed, but Lazard's relative gain from a much lower base looks modest next to Evercore's. The Wikipedia attention signal is worth flagging as colour: retail attention hit a z-score of 3.1 against the prior 90-day history as of late September, the highest reading in the dataset. It carries no measured link to Lazard's reported figures, so it is attention, not a signal, but it does suggest the stock has moved onto more watchlists in recent weeks, likely driven by the sharp price decline and the approaching print.
Lazard does carry a genuine bull case into October 22. U.S. M&A announcement volumes were running 32% ahead of last year's pace in Q3, and European deal activity was up 26%. The firm's public advisory pipeline grew 8.2% from Q2-end, while peers on average contracted 6.7%. Whether that pipeline momentum converted into completed fee revenue is the question the earnings release will answer. The most recent quarterly print in July produced a modest positive 1-day move of 1.8%, but the stock then gave back 3.7% over the following week, a pattern that suggests the market has been quick to fade post-print optimism in recent cycles.
The October 22 number reduces to a single question: did the M&A announcement surge of Q3 translate into closed deals and advisory fees, or does an M&A recovery that is still in the announcement phase leave Lazard's revenue picture looking more like 2024 than the recovery year the bull case describes.
See the live data behind this article on ORTEX.
Open LAZ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
